Physician profile
Stephen Hannah
NPI 1649620584
$5,689.12
in general payments reported to CMS, 2019-2025
31 companies · $971 in 2025
The $971 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,085 · 2022: $1,389 · 2023: $1,087 · 2024: $1,158 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,126 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,126.21 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,148.12 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $853.90 | 2021-2025 | |
| Edwards Lifesciences Corporation | $479.54 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $395.33 | 2021-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $375.90 | 2021-2024 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $370.57 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $240.96 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.66 | 2021-2025 | Jardiance |
| Amgen INC. | $196.26 | 2021-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $192.27 | 2021-2022 | |
| Abiomed | $187.33 | 2022-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $120.77 | 2021-2025 | Wainua |
| Amarin Pharma, INC. | $117.24 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $113.97 | 2024 | Arcalyst |
| Medtronic, INC. | $86.71 | 2021-2023 | Linq II |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $74.38 | 2022-2023 | |
| Cvrx, INC. | $60.10 | 2023-2024 | Barostim Neo System |
| Boston Scientific Corporation | $54.26 | 2021-2025 | Bodyguardian, General - Therapies |
| Esperion Therapeutics, INC. | $52.93 | 2021-2024 | Nexletol |
| Scpharmaceuticals INC. | $40.61 | 2024-2025 | |
| Astellas Pharma US INC | $38.57 | 2021-2022 | |
| Baxter Healthcare | $36.12 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $34.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.54 | 2022-2025 | |
| Inspire Medical Systems, INC. | $31.41 | 2024 | Inspire |
| Kowa Pharmaceuticals America, INC. | $26.30 | 2021 | |
| Daiichi Sankyo INC. | $20.31 | 2024 | Injectafer |
| Novo Nordisk INC | $20.13 | 2023 | Wegovy |
| Abbott Laboratories | $18.73 | 2022 | |
| Inogen, INC. | $15.81 | 2022 | |
| Cardiovascular Systems INC. | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hannah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.